Porton Pharma Solutions Ltd. provides contract development and manufacturing organization (CDMO) solutions for small molecules, tides, biologics, and conjugates...
Porton Advanced's UC-MSCs Cell Bank for Exosome Manufacturing Receives U.S. FDA Drug Master File (DMF) Acceptance
07:08 ETChina-US Dual Filing Success: Porton Advanced's End-to-End Bacterial Vector CDMO Solution Accelerates NMPA Approval of Salvectors' Innovative Oncolytic Bacteria Therapy
Porton released its performance for the first three quarters, with a net profit attributable to the parent company of 79.9154 million yuan, an increase of 138.71%
Porton issued a profit warning, expecting a net profit attributable to shareholders of 73.2 million to 88.2 million yuan in the first three quarters, turning losses into profits
Innovative drug concept stocks fluctuate and rise, DEZHAN HEALTHCARE hits the limit up
Zhejiang Merchants Securities: The growth trend of the CXO sector in 25H1 continues to improve, and the construction projects remain at a high level